CCL2 and metabolic dysfunction-associated steatohepatitis: One small (n = 14) RCT in patients with MASH treated with liraglutide 1.8 mg found significant reductions in cholesterol‐LDL (−0.7 vs. +0.05 mmol/L; p < 0.01), ALT (−54 vs. −4.0 IU/L; p < 0.01), and serum leptin, adiponectin, and CCL‐2 (all p < 0.05).